An International Single-Arm Study to Provide Further Safety and Efficacy Data on the Bortezomib(Velcade)/Melphalan/Prednisone Regimen in Previously Untreated Transplant Ineligible Multiple Myeloma Patients

Trial Profile

An International Single-Arm Study to Provide Further Safety and Efficacy Data on the Bortezomib(Velcade)/Melphalan/Prednisone Regimen in Previously Untreated Transplant Ineligible Multiple Myeloma Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan (Primary) ; Prednisone (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access; Registrational; Therapeutic Use
  • Sponsors Janssen Inc
  • Most Recent Events

    • 03 May 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
    • 12 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top